521 related articles for article (PubMed ID: 32042038)
1. Emotions and brain function are altered up to one month after a single high dose of psilocybin.
Barrett FS; Doss MK; Sepeda ND; Pekar JJ; Griffiths RR
Sci Rep; 2020 Feb; 10(1):2214. PubMed ID: 32042038
[TBL] [Abstract][Full Text] [Related]
2. Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.
Kraehenmann R; Preller KH; Scheidegger M; Pokorny T; Bosch OG; Seifritz E; Vollenweider FX
Biol Psychiatry; 2015 Oct; 78(8):572-81. PubMed ID: 24882567
[TBL] [Abstract][Full Text] [Related]
3. Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression.
Roseman L; Demetriou L; Wall MB; Nutt DJ; Carhart-Harris RL
Neuropharmacology; 2018 Nov; 142():263-269. PubMed ID: 29288686
[TBL] [Abstract][Full Text] [Related]
4. Neural Mechanisms of Resting-State Networks and the Amygdala Underlying the Cognitive and Emotional Effects of Psilocybin.
Stoliker D; Novelli L; Vollenweider FX; Egan GF; Preller KH; Razi A
Biol Psychiatry; 2024 Jul; 96(1):57-66. PubMed ID: 38185235
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression.
Mertens LJ; Wall MB; Roseman L; Demetriou L; Nutt DJ; Carhart-Harris RL
J Psychopharmacol; 2020 Feb; 34(2):167-180. PubMed ID: 31941394
[TBL] [Abstract][Full Text] [Related]
6. Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis.
Carhart-Harris RL; Leech R; Erritzoe D; Williams TM; Stone JM; Evans J; Sharp DJ; Feilding A; Wise RG; Nutt DJ
Schizophr Bull; 2013 Nov; 39(6):1343-51. PubMed ID: 23044373
[TBL] [Abstract][Full Text] [Related]
7. Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination.
Grimm O; Kraehenmann R; Preller KH; Seifritz E; Vollenweider FX
Eur Neuropsychopharmacol; 2018 Jun; 28(6):691-700. PubMed ID: 29703645
[TBL] [Abstract][Full Text] [Related]
8. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors.
Kometer M; Schmidt A; Bachmann R; Studerus E; Seifritz E; Vollenweider FX
Biol Psychiatry; 2012 Dec; 72(11):898-906. PubMed ID: 22578254
[TBL] [Abstract][Full Text] [Related]
9. Elevated striatal and decreased dorsolateral prefrontal cortical activity in response to emotional stimuli in euthymic bipolar disorder: no associations with psychotropic medication load.
Hassel S; Almeida JR; Kerr N; Nau S; Ladouceur CD; Fissell K; Kupfer DJ; Phillips ML
Bipolar Disord; 2008 Dec; 10(8):916-27. PubMed ID: 19594507
[TBL] [Abstract][Full Text] [Related]
10. Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression.
Stroud JB; Freeman TP; Leech R; Hindocha C; Lawn W; Nutt DJ; Curran HV; Carhart-Harris RL
Psychopharmacology (Berl); 2018 Feb; 235(2):459-466. PubMed ID: 29085980
[TBL] [Abstract][Full Text] [Related]
11. Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals.
McCulloch DE; Madsen MK; Stenbæk DS; Kristiansen S; Ozenne B; Jensen PS; Knudsen GM; Fisher PM
J Psychopharmacol; 2022 Jan; 36(1):74-84. PubMed ID: 34189985
[TBL] [Abstract][Full Text] [Related]
12. The neural substrates of affective processing in depressed patients treated with venlafaxine.
Davidson RJ; Irwin W; Anderle MJ; Kalin NH
Am J Psychiatry; 2003 Jan; 160(1):64-75. PubMed ID: 12505803
[TBL] [Abstract][Full Text] [Related]
13. The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity.
Kraehenmann R; Schmidt A; Friston K; Preller KH; Seifritz E; Vollenweider FX
Neuroimage Clin; 2016; 11():53-60. PubMed ID: 26909323
[TBL] [Abstract][Full Text] [Related]
14. Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin.
Carhart-Harris RL; Leech R; Williams TM; Erritzoe D; Abbasi N; Bargiotas T; Hobden P; Sharp DJ; Evans J; Feilding A; Wise RG; Nutt DJ
Br J Psychiatry; 2012 Mar; 200(3):238-44. PubMed ID: 22282432
[TBL] [Abstract][Full Text] [Related]
15. Nicotine increases neural response to unpleasant stimuli and anxiety in non-smokers.
Kobiella A; Ulshöfer DE; Vollmert C; Vollstädt-Klein S; Bühler M; Esslinger C; Smolka MN
Addict Biol; 2011 Apr; 16(2):285-95. PubMed ID: 20731637
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
Grob CS; Danforth AL; Chopra GS; Hagerty M; McKay CR; Halberstadt AL; Greer GR
Arch Gen Psychiatry; 2011 Jan; 68(1):71-8. PubMed ID: 20819978
[TBL] [Abstract][Full Text] [Related]
17. Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin.
Lord LD; Expert P; Atasoy S; Roseman L; Rapuano K; Lambiotte R; Nutt DJ; Deco G; Carhart-Harris RL; Kringelbach ML; Cabral J
Neuroimage; 2019 Oct; 199():127-142. PubMed ID: 31132450
[TBL] [Abstract][Full Text] [Related]
18. Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat.
Smigielski L; Kometer M; Scheidegger M; Krähenmann R; Huber T; Vollenweider FX
Sci Rep; 2019 Oct; 9(1):14914. PubMed ID: 31649304
[TBL] [Abstract][Full Text] [Related]
19. Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations.
Kometer M; Pokorny T; Seifritz E; Volleinweider FX
Psychopharmacology (Berl); 2015 Oct; 232(19):3663-76. PubMed ID: 26231498
[TBL] [Abstract][Full Text] [Related]
20. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.
Carbonaro TM; Bradstreet MP; Barrett FS; MacLean KA; Jesse R; Johnson MW; Griffiths RR
J Psychopharmacol; 2016 Dec; 30(12):1268-1278. PubMed ID: 27578767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
